These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 9750583)

  • 1. [Therapeutic monitoring of teicoplanin in a severely burned patient].
    Lesne-Hulin A; Bourget P; Le Bever H; Ainaud P; Carsin H
    Ann Fr Anesth Reanim; 1997; 16(4):374-7. PubMed ID: 9750583
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of a single dose of teicoplanin in burn patients.
    Steer JA; Papini RP; Wilson AP; Dhillon S; Hichens MF; McGrouther DA; Frame JD; Parkhouse N
    J Antimicrob Chemother; 1996 Mar; 37(3):545-53. PubMed ID: 9182111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical efficacy and safety in patients treated with teicoplanin with a target trough concentration of 20 μg/mL using a regimen of 12 mg/kg for five doses within the initial 3 days.
    Ueda T; Takesue Y; Nakajima K; Ichiki K; Ishikawa K; Takai Y; Yamada K; Tsuchida T; Otani N; Takahashi Y; Ishihara M; Takubo S; Ikeuchi H; Uchino M; Kimura T
    BMC Pharmacol Toxicol; 2020 Jul; 21(1):50. PubMed ID: 32641110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced loading regimen of teicoplanin is necessary to achieve therapeutic pharmacokinetics levels for the improvement of clinical outcomes in patients with renal dysfunction.
    Ueda T; Takesue Y; Nakajima K; Ichiki K; Doita A; Wada Y; Tsuchida T; Takahashi Y; Ishihara M; Ikeuchi H; Uchino M; Kimura T
    Eur J Clin Microbiol Infect Dis; 2016 Sep; 35(9):1501-9. PubMed ID: 27278654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The pharmacokinetics of teicoplanin in infants and children.
    Reed MD; Yamashita TS; Myers CM; Blumer JL
    J Antimicrob Chemother; 1997 Jun; 39(6):789-96. PubMed ID: 9222049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of initial loading procedure for teicoplanin in critically ill patients with severe infections.
    Matsumoto K; Kanazawa N; Watanabe E; Yokoyama Y; Fukamizu T; Shimodozono Y; Maeda C; Yasuda T; Kakihana Y; Ikawa K; Morikawa N; Takeda Y
    Biol Pharm Bull; 2013; 36(6):1024-6. PubMed ID: 23727923
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population pharmacokinetics of teicoplanin administered by subcutaneous or intravenous route and simulation of optimal loading dose regimen.
    Cazaubon Y; Venisse N; Mimoz O; Maire P; Ducher M; Bourguignon L; Goutelle S
    J Antimicrob Chemother; 2017 Oct; 72(10):2804-2812. PubMed ID: 29091222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimal teicoplanin loading regimen to rapidly achieve target trough plasma concentration in critically ill patients.
    Li H; Gao L; Zhou L; Wang Y; Li Q; Wang J; Chen T; Zhang Y; Wang T; Shi Q
    Basic Clin Pharmacol Toxicol; 2020 Mar; 126(3):277-288. PubMed ID: 31608579
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determination of teicoplanin trough concentration target and appropriate total dose during the first 3 days: a retrospective study in patients with MRSA infections.
    Matsumoto K; Kanazawa N; Ikawa K; Fukamizu T; Shigemi A; Yaji K; Shimodozono Y; Morikawa N; Takeda Y; Yamada K
    J Infect Chemother; 2010 Jun; 16(3):193-9. PubMed ID: 20195882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recommended initial loading dose of teicoplanin, established by therapeutic drug monitoring, and outcome in terms of optimal trough level.
    Sato M; Chida K; Suda T; Muramatsu H; Suzuki Y; Hashimoto H; Gemma H; Nakamura H
    J Infect Chemother; 2006 Aug; 12(4):185-9. PubMed ID: 16944256
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population pharmacokinetics of teicoplanin in children.
    Ramos-Martín V; Paulus S; Siner S; Scott E; Padmore K; Newland P; Drew RJ; Felton TW; Docobo-Pérez F; Pizer B; Pea F; Peak M; Turner MA; Beresford MW; Hope WW
    Antimicrob Agents Chemother; 2014 Nov; 58(11):6920-7. PubMed ID: 25224001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Influence of arteriovenous hemofiltration on teicoplanin pharmacokinetics].
    Choufane S; Lobjoie E; Tinturier F
    Ann Fr Anesth Reanim; 1996; 15(8):1168-72. PubMed ID: 9636789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Teicoplanin versus flucloxacillin in the treatment of infection following burns.
    Steer JA; Papini RP; Wilson AP; McGrouther DA; Parkhouse N
    J Antimicrob Chemother; 1997 Mar; 39(3):383-92. PubMed ID: 9096188
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating the optimal dose of teicoplanin with therapeutic drug monitoring: not too high for adverse event, not too low for treatment efficacy.
    Kim SH; Kang CI; Huh K; Cho SY; Chung DR; Lee SY; Kim YJ; Peck KR
    Eur J Clin Microbiol Infect Dis; 2019 Nov; 38(11):2113-2120. PubMed ID: 31372903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and pharmacodynamics of sequential intravenous and subcutaneous teicoplanin in critically ill patients without vasopressors.
    Barbot A; Venisse N; Rayeh F; Bouquet S; Debaene B; Mimoz O
    Intensive Care Med; 2003 Sep; 29(9):1528-34. PubMed ID: 12856119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical pharmacokinetics of teicoplanin.
    Wilson AP
    Clin Pharmacokinet; 2000 Sep; 39(3):167-83. PubMed ID: 11020133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Significance of individual adjustment of initial loading dosage of teicoplanin based on population pharmacokinetics.
    Niwa T; Imanishi Y; Ohmori T; Matsuura K; Murakami N; Itoh Y
    Int J Antimicrob Agents; 2010 May; 35(5):507-10. PubMed ID: 20185275
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population pharmacokinetics of teicoplanin and attainment of pharmacokinetic/pharmacodynamic targets in adult patients with haematological malignancy.
    Byrne CJ; Roberts JA; McWhinney B; Ryder SA; Fennell JP; O'Byrne P; Deasy E; Egan S; Desmond R; Enright H; D'Arcy DM; McHugh J
    Clin Microbiol Infect; 2017 Sep; 23(9):674.e7-674.e13. PubMed ID: 28267636
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population pharmacokinetic study of teicoplanin in severely neutropenic patients.
    Lortholary O; Tod M; Rizzo N; Padoin C; Biard O; Casassus P; Guillevin L; Petitjean O
    Antimicrob Agents Chemother; 1996 May; 40(5):1242-7. PubMed ID: 8723474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population Pharmacokinetics and Pharmacodynamics of Teicoplanin and C-Reactive Protein in Hospitalized Patients With Gram-Positive Infections.
    Ogami C; Tsuji Y; Muraki Y; Mizoguchi A; Okuda M; To H
    Clin Pharmacol Drug Dev; 2020 Feb; 9(2):175-188. PubMed ID: 30934169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.